Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby
restoring normal tissue function,–. The interaction of menin with lysine methyltransferase 2A …

Background Patients with acute myeloid leukaemia (AML) positive for internal tandem
duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent …

The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and
limited treatment options. Here we provide a comprehensive census of the bone marrow …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …